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Abstract
Background: The purpose of this study was to identify chronic urticaria (CU) etiologies and treatment modalities in
Ecuador. We propose that the sample distribution fits the expected one, and that there is an association between
the etiology and its treatment.
Methods: We performed a retrospective study involving 112 patients diagnosed with CU using a Checklist for a
complete chronic urticaria medical history. Demographic and clinical variables were collected. The etiology of CU
was classified using the EAACI/GA2LEN/EDF/WAO guideline. Descriptive analyses were performed for demographical
and clinical variables. Chi square tests were applied to analyze the fit of distribution and the independence of variables.
P values less than 0.05 were considered significant.
Results: Among all the patients, 76.8% were diagnosed with chronic spontaneous urticaria (CSU), of which 22.3% had
a known etiology or possible exacerbating condition. Food allergy was identified as the most common accompanying
condition in patients with CSU (10.7%) (p < 0.01).. On the other hand, 23.2% inducible urticarias (CIndU) were indentified;
dermographism was the most common (10.7%) (p < 0.01).
Regarding treatment regimens, sg-H1-antihistamines alone represented the highest proportion (44.6%). The combination
of any H1-antihistamine plus other drug was a close second (42.0%) (p < 0.01). Almost 48% of CSUs of unknown etiology
were treated with any antihistamine plus another drug. In patients with known etiology, sg-antihistamines alone (44.0%)
was the most common management. In addition, 53.8% of CIndUs were treated with sg-antihistamines alone. Though,
these associations were not statistically significant.
Conclusion: CSU is the most frequent subtype of CU. Modern non-sedating antihistamines in licensed doses are the
drug of choice. Nevertheless, a great proportion of patients require the addition of another type of medication.
Keywords: Chronic urticaria, Chronic spontaneous urticaria, Chronic inducible urticaria, Autoimmune thyroid diseases,
Urticarial vasculitis, Antihistamine
Background
Urticaria is defined by the presence of hives that appear
and resolve within 24 h. Urticarial lesions can be
circumscribed, raised, erythematous plaques, with central
pallor. They can adopt different shapes and sizes (round,
annular, or serpiginous), and are characterized by three
main features: swelling and erythema; itching/burning
sensation; spontaneous resolution within 24 h [1].
With regard to the duration of urticaria, it can be clas-
sified as “acute” (< 6 weeks) or “chronic” (> 6 weeks) [2].
Among patients with chronic urticaria, ≤ 40% can have
accompanying episodes of angioedema (defined as a sud-
den swelling of the deep dermis in well-circumscribed
areas like the lips, periorbital area, extremities, and geni-
tals) [3, 4].
According to its underlying etiology, chronic urticaria is
classified in two main groups: (i) chronic spontaneous
urticaria (formerly known as “chronic idiopathic
urticaria”), and (ii) inducible urticaria (including cold,
delayed pressure, solar, heat, vibratory, cholinergic,
contact, and aquagenic) [1].
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Despite recent updates to the management guidelines for
urticaria, it remains a challenge for healthcare providers to
diagnose and identify each subtype of chronic urticaria due
to the broad spectrum of clinical manifestations, and the
possibility that several subtypes of the disease coexist in
the same patient [5, 6]. Among physicians in Ecuador, a
recent study suggested a low awareness of existing guide-
lines, resulting in poor knowledge of how to diagnose and
treat the disease. It seems that the limited time per consult-
ation (specially in public hospitals due to the volume of
patients), together with low participation in medical meet-
ings and conferences, led to poor adherence and applica-
tion of current guidelines. Thus, patients were less likely to
receive the recent evidence based treatments and
diagnostic approaches [7].
With regard to treatment, two major research teams
have published guidelines based on the available evidence
and expert opinion [5, 6]. The US Joint Task Force on
Practice Parameters (JTFPP) promotes a four-step
approach, whereas guidelines set by EAACI/GA2LEN/
EDF/WAO (European Academy of Allergology and
Clinical Immunology, Global Allergy and Asthma
European Network, European Dermatology Forum and
World Allergy Organization) advocate a simplified three-
step approach. Both guidelines agree on second-generation
H1 antihistamines as the cornerstone and first-line therapy
for chronic urticaria [4]. Treatment failure can prompt a
dose increase of up to fourfold according to European
guidelines or, in the case of the US guidelines: addition of
another second-generation antihistamine, combination
therapy with a first- and second-generation H1 antihista-
mine, or the addition of a leukotriene receptor antagonist
as the next step. Both guidelines also agree upon the inclu-
sion of omalizumab, cyclosporine, corticosteroids, and
immunosuppressants to treatment if the initial regimen
fails [8, 9]. However, in developing countries, where access
to omalizumab is not provided by medical insurance, the
affordability is very low [10, 11].
Data regarding the prevalence, demographics, and
clinical characteristics of patients with chronic urticaria
in Latin America, specifically in Ecuador, is limited. We
aimed to fill this knowledge gap by describing the most
common features and treatment choices of patients with
chronic urticaria in Guayaquil, Ecuador.
Methods
We carried out a retrospective study involving 112 pa-
tients diagnosed with chronic urticaria from 2005 to
2016 at Respiralab Research Center, Guayaquil-Ecuador.
Demographic and clinical variables such as age, sex,
years with the disease, type of urticarial, and medications
were collected using medical records from the institu-
tion. The etiology of chronic urticaria was classified
using EAACI/GA2LEN/EDF/WAO [5]. The diagnosis
was effected using a checklist designed for chronic urti-
caria [12]. These check list items covered two main
areas: Essential features for anamnesis and diagnosis of
CU and typical symptoms/parameters or characteristics
according to CU subtype, etiology, and laboratory find-
ings. We developed an easy-to-use tool to support the
early correct diagnosis and management of CU and fa-
cilitate healthcare providers/physicians’ diagnostic
workup, clinical approach and allow to select the best
approach for treatment in patients with CU.
Medications were subclassified into four groups: first-
generation H1 antihistamine alone; second-generation H1
antihistamine alone; first- and second-generation H1 anti-
histamine combined; any H1 antihistamine with other
types of medications (including, but not limited to, corti-
costeroids, topical agents, leukotriene inhibitors, and
biologic therapy). These therapeutic modalities apply only
to treatment initiation; no follow up or treatment modifi-
cations are described in this study.Descriptive analyses
(frequency, percentage, standard deviation) were carried
out for demographic and clinical variables. The chi-square
test was applied to analyze the fit of distribution as well as
the independence of variables. All statistical analyses were
carried out using SPSS v24.0 (IBM, Armonk, NY, USA). P
< 0.05 was considered significant.
Results
Among the 112 patients studied, 69.6% were female and
30.4% were male, with the age ranging from 14 to 73
(mean, 35.8; SD, 13.8) years. The mean duration of
suffering from chronic urticaria was 1.6 (SD 2.2) years
(Table 1).
Urticaria type
In our data, 76.8% of patients were diagnosed with
chronic spontaneous urticaria and 23.2% with chronic
inducible urticaria (p = 0.001) (Table 2).
Among all patients, 54.5% of cases had chronic spon-
taneous urticaria of unknown etiology, whereas the
etiology was identified in 22.3%. With regard to the
known etiology, food allergy was a relevant accompanying
condition in 10.7% of all cases of chronic urticaria, while
drugs accounted for 4.5% of cases. CSU with food allergy,
described those patients presenting with chronic urticaria
and accompanying food allergy, which was assessed
Table 1 – Demographic information of studied population
Characteristics Patients (n=) n (%)
Age (years) 35.8 (13.8)
Years with urticaria 1.6 (2.2)
Gender
Male 34 (30.4)
Female 78 (69.6)
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through anamnesis and specific IgE [13]. Although the role
of food allergy in chronic urticaria is highly controversial at
the moment, current guidelines include immune mediated
type I reactions (drugs, food, infections) in the diagnostic
workup for CSU patients [5]. For this reason, we believe it
is necessary to include food allergies as relevant conditions
in our patients. Further research is needed to improve our
understanding between food and determine their possible
role, if any, in the pathogenesis of CSU.
On the other hand, drug associated urticaria included
patients with chronic urticaria triggered by drug allergy,
which was diagnosed through careful anamnesis and
confirmed by urticaria symptoms resolution after
removal of the offending drug, as suggested by the
EAACI/GA2LEN/EDF/WAO guideline [5]. Also, 3.6% of
cases were associated with chronic autoimmune
urticaria, while 3.6% were associated with thyroid disease
(p = 0.00) (Fig. 1).
The most prevalent type of inducible urticaria was der-
mographism (10.7%), followed by vibratory angioedema
(5.4%), cholinergic urticaria (2.7%), with 1.8% for both
delayed-pressure urticaria and cold urticaria, and 0.9%
for solar urticarial (p = 0.00) (Table 2).
Treatment
With regard to treatment subgroups, the most prescribed
regimen was a second-generation H1 antihistamine alone
(44.6%). The combination of any H1 antihistamine
(regardless of generation) plus another type of treatment
(including autologous blood, topical agents, corticoste-
roids, anti-leukotriene agents, hydroxychloroquine or
omalizumab) was also used widely (42.0%). A combination
of a first- and second-generation H1 antihistamine was
used in 10.7% of cases, whereas only 2.7% were prescribed
Table 2 – Urticaria diagnosis of studied population according
to the EAACI/GA2LEN/EDF/WAO guidelines
Urticaria type Overall patients (n = 112) n (%)
Chronic Spontaneous Urticaria 86 (76.8)
CSU of unknown etiology 61 (54.5)
CSU of known etiology 25 (22.3)
CSU with food allergy 12 (10.7)
Drug associated Urticaria 5 (4.5)
Thyroid Associated Urticaria 4 (3.6)
Chronic Autoimmune Urticaria 4 (3.6)
Chronic Inducible Urticaria 26 (23.2)
Symptomatic Dermographism 12 (10.7)
Cold Urticaria 2 (1.8)
Delayed pressure urticaria 2 (1.8)
Solar Urticaria 1 (0.9)
Vibratory Angioedema 6 (5.4)
Cholinergic Urticaria 3 (2.7)
All data are presented as frequencies and percentages. The chi-square goodness-of-fit
test indicated that the proportions of urticaria subtypes diagnosed in the study were
statistically significant (p=0.00). CSU chronic spontaneous urticaria
Fig. 1 – Proportion of chronic urticaria etiologies in studied population
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with a first-generation antihistamine alone (p = 0.00)
(Table 3).
Urticaria type and treatment
Almost 48% of patients diagnosed with chronic spontan-
eous urticaria of unknown etiology were treated with any
antihistamine plus another drug, and 41.0% were treated
with a second-generation antihistamine alone. However,
for patients with known etiology, the most common treat-
ment was a second-generation antihistamine alone
(44.0%). In addition, 53.8% of patients with chronic indu-
cible urticaria were prescribed a second-generation anti-
histamine alone, and 30.8% required an antihistamine
associated with another medication. However, this associ-
ation between the type of urticaria and treatment was not
statistically significant (p = 0.76) (Fig. 2).
Discussion
Chronic urticaria is widely recognized as a relatively com-
mon disease that necessitates consultation with a derma-
tologist and/or allergist. Maurer and coworkers suggested
that 66–93% of patients with chronic urticaria are diag-
nosed with the chronic spontaneous variant, 4–33% with
physical urticaria, and 1–7% with cholinergic urticaria
[14]. Our results are similar to the data obtained from the
study by Maurer and colleagues.
Among chronic urticaria in Latin America, our
demographic findings were comparable with the study
by Gomez et al.; patients were were predominantly
women, with a median age ranging in the 30s, and in
average one and a half years with the disease (1.7 years
in the Argentinian records) [15]. Treatment schemes
were also similar, most patients were prescribed with
second generation H1 antihistamines as a first line
therapy.
In a previous study conducted from 2002 to 2004 in
Ecuador, 161 patients diagnosed with chronic urticaria
were classified according to guidelines set by the British
Society for Allergy and Clinical Immunology [16].
Approximately 60% of those patients had a diagnosis
that was compatible with chronic idiopathic urticaria
[17]. Those findings, translated to the new EAACI/
GA2LEN/EDF/WAO classification, would suggest that
the proportion of patients with chronic spontaneous
urticaria has not changed from 2005 to the present day
in our local setting.
It is difficult to determine the role of food as an allergen
in the induction of chronic urticarias for four main rea-
sons. First, identification of a food as a trigger depends on
medical history, which is often unreliable. Second, the
results of elimination diets are considered contradictory.
Third, measuring the allergen-specific immunoglobulin
(Ig)E level for food has a poor positive predictive value.
Finally, the results of double-blind placebo-controlled oral
food challenge are difficult to interpret [18]. Similar to the
prevalence reported by Kaeser et al., we found ≈10% of
cases CSU with food allergy in our study. However, other
studies in Asiatic populations have reported a prevalence
of 1.1 and 2.8% [19, 20].
The second most common etiology reported by our
patients with chronic spontaneous urticaria was induced
by drugs. Kozel et al. published a study with 220 adults
diagnosed with urticaria, of which 9.0% of cases were
caused by drug allergies [21]. In the present study, the
prevalence of drug-induced urticaria was more than
double compared with that in our previous study (4.5%
vs. 2%) [17]. Jares and colleagues reported that, in a
Latin American population, urticaria and angioedema
were the most prevalent clinical features (71%) in
hypersensitivity reactions triggered by drugs. Nonsteroidal
anti-inflammatory drugs and antibiotics were the most
frequently used drugs in those patients. These drugs are
sold over-the-counter, which can encourage their
abuse [22].
Confino-Cohen et al. found a strong association
between chronic urticaria and major autoimmune
diseases. They also reported thyroid diseases to be the
most common autoimmune diseases in patients with
chronic urticaria [23]. To illustrate this correlation bet-
ter, Kim and colleagues revealed that individuals with
autoimmune thyroid diseases (AITD) were more likely
to develop chronic spontaneous urticaria than a normal
population (hazard ratio, 1.46; 95% confidence interval,
1.25–1.70). Those data demonstrated a significant
association between AITD and chronic spontaneous ur-
ticaria [24]. Furthermore, autoimmune hypothyroidism
and autoimmune hyperthyroidism have been said to be
associated with chronic spontaneous urticaria, although
the former appears to be far more common (9.8%) [23].
We found that 7.2% of cases with chronic spontaneous
urticaria were associated with autoimmune disease, of
which 3.6% were due to thyroid disease. In our patients,
we confirmed the diagnosis of AITD with antithyroid
antibodies above the reference range independently of
the level of thyroid hormones. Compared with our previ-
ous study, the prevalence of chronic spontaneous
Table 3 – Treatment modality prescribed in studied population
Treatment Overall patients (n = 112) n
(%)
Sg H1-antihisatmine alone 50 (44.6)
Sg H1-antihisatmine + another drug 47 (42.0)
Fg H1-antihistamine + Sg H1-
antihisatmine
12 (10.7)
Fg H1-antihisatmine 3 (2.7)
All data are presented as frequencies and percentages. The chi-square goodness-of-fit
test indicated that the proportions of treatment modalities prescribed in the study
were statistically significant (p = 0.00). Fg H1-antihistamine, first-generation H1
antihistamine; Sg H1-antihisatmine, second-generation H1 antihistamine
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urticaria associated with thyroid disease was reduced
(3.6% vs. 6.0%) [17].
There is a subgroup of patients with chronic spontaneous
urticaria who have autoantibodies against IgE or its recep-
tor: FcεRI [25]. These autoantibodies act as activators of
mast cells, leading to their degranulation and intracellular
pathway signaling. This pathogenic condition is most com-
monly referred in clinical practice as “chronic autoimmune
urticaria” [26]. The presence of these autoantibodies may
be clinically important in a group of severely affected,
treatment-resistant patients who might benefit from immu-
nomodulatory agents [27]. A position paper proposed that
the ‘gold standard’ for the diagnosis of autoimmune chronic
spontaneous urticaria should be a combination of: (i) a
positive in vitro biologic test to demonstrate the functional-
ity of autoantibodies (basophil histamine release test or the
expression of a marker of basophil activation such as clus-
ter of differentiation (CD)63 or CD203c using flow cytome-
try), (ii) positive autologous serum skin test (ASST) to
demonstrate the in vivo relevance of mast-cell degranula-
tion and the increase in capillary permeability, and (iii) a
positive immunologic assay for autoantibodies against
FcεRIα receptors (western blotting or enzyme-linked
immunosorbent assay) to demonstrate the specificity of
autoantibodies [28].
Autoimmunity has been reported to be an etiologic
factor in 40–60% of cases of chronic spontaneous
urticaria [29]. In our patients, we confirmed the
diagnosis with an ASST interpreted according to
international guidelines [5]. Briefly, 0.05 mL of serum and
0.05 mL of plasma were injected intradermally. Histamine
was used as a positive control and physiologic (0.9%) saline
solution as a negative control. A minimum difference of
1.5 mm in wheal size between the positive control and
negative control after 30 min was considered to be a posi-
tive test [30]. Even though the ASST has a low positive
predictive value (≈55.1%), it represents the only screening
tool available in daily clinical practice for most physicians
due to its simplicity and cost-effectiveness [31]. However, a
positive ASST in a patient with chronic urticaria can only
suggest “autoreactivity” because its primary objective is to
exclude the diagnosis [30]. Unfortunately, as in many other
Latin American countries, we do not have confirmatory
tests readily available to establish the actual diagnosis of
autoimmune chronic spontaneous urticaria. In fact, only
12.9% of physicians in our country use the ASST, in line
with guideline recommendations (7). This could explain
why we diagnosed few patients with autoimmune chronic
spontaneous urticaria.
Chronic inducible urticaria is characterized by itchy
wheals, flare-type skin reactions, and/or angioedema in-
duced by external physical factors. The latter can be
mechanical (friction, pressure, vibration), thermal (cold,
heat) stimuli, or electromagnetic radiation (solar radiation)
[32]. Abajian and colleagues estimated the prevalence of
chronic inducible urticaria to be 13.1–14.9% among pa-
tients with chronic urticaria [33]. Our findings are similar
to those of Sanchez et al., who reported a prevalence of
36.3% among Latin American patients [34].
The most prevalent type of chronic inducible urticaria
is symptomatic dermographism [35]. The latter was rep-
resented in 9.7% of our patients, but this prevalence was
much lower than that reported by Sanchez et al., in
which 24.8% tests tested positive for symptomatic der-
mographism [34]. Nevertheless, this prevalence was
comparable with that reported in our previous study
[17]. Environmental factors, such as geographic charac-
teristics, could have had a key role in the differences be-
tween our results and the data of Sanchez et al. For
instance, Bogotá in Colombia is located 2630 m above
sea level and has an average temperature of 14.0 °C.
Guayaquil is located 6 m above sea level and has an
Fig. 2 – Frequencies of treatment modalities prescribed by chronic urticaria subtype
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average temperature of 30.8 °C. Also, Schoepke et al.
strongly suggested that dermographism might be precip-
itated by environmental factors or adverse events in life
after observing that the peak age of onset of dermo-
graphism presented in the second and third decades of
life [35].
In the study by Sanchez et al., cold urticaria was re-
ported to be the second most prevalent type of chronic
inducible urticaria. However, we found vibratory angio-
edema to be the second most prevalent type of chronic
inducible urticaria. In addition, Sanchez hypothesized
that exposure to cold environments might protect
against cold urticaria. Interestingly, the prevalence of
cold urticaria in our sample was one of the lowest, even
though our patients were not exposed to low tempera-
tures. Thus, we agree with Sanchez et al. that
temperature or altitude are not the only determining fac-
tors in the development of chronic inducible urticaria.
Although urticarial vasculitis is not a subtype of
chronic urticaria, it is a relevant syndrome to exclude in
a patient whose chief complaint is an urticarial eruption
accompanied by angioedema. In urticarial vasculitis, the
lesions are painful, burning, and tender, with plaques
lasting for > 24 h (sometimes ≤ 72 h). The wheals are as-
sociated with residual purpura or hyperpigmentation,
and occasionally have a central dark-red or brown mac-
ule signifying underlying purpura and vasculitis. Other
characteristics of urticarial vasculitis are swelling, re-
sidual bruising, and edema from focused pressure. Up to
81% of patients might present with extracutaneous
symptoms, as reported in one retrospective study of 47
patients [36]. Skin biopsy must be undertaken to con-
firm or reject the diagnosis [37–39].
In our transversal study, we diagnosed 12 patients with
urticarial vasculitis. If such patients were to be added to
the sample of patients with chronic urticaria, it would
represent 9.68% of all diagnoses. Hence, we consider it
relevant to include urticarial vasculitis in the differential
diagnosis of chronic urticaria. Thus, we highlight how
such an entity must always be ruled out.
Despite the recent update of the EAACI/GA2LEN/
EDF/WAO guidelines for chronic urticaria, the manage-
ment of chronic spontaneous urticaria differs among
various parts of the world [5, 7, 40]. As with clinical
guidelines, published expert opinions recommend
second-generation antihistamines as the preferred first-
line treatment for chronic urticaria [41]. Patients who
have unsatisfactory responses to standard doses of
second-generation antihistamines should receive doses
up to fourfold higher than the standard dose before al-
ternative therapies are considered [5]. However, the
addition of an H2-antagonist or a first-generation
antihistamine to be taken at bedtime is another
possibility [6].
In our study, a second-generation H1 antihistamine
alone was the most common medication type prescribed,
followed by antihistamines combined with other types of
treatment (including autologous blood, topical agents, cor-
ticosteroids, antileukotriene agents, hydroxychloroquine
or omalizumab). In a recent study, we found that only
one-third of physicians reported using regular doses of
second-generation H1 antihistamines as first-line treat-
ment, and that specialists (dermatologists/allergologists)
prescribed them more frequently [7]. Conversely, only
12.9% of physicians prescribed second-generation H1 anti-
histamines at higher doses when treating patients with
chronic urticaria as second-line treatment [7].
Increasing the dose of second-generation H1 antihista-
mines up to fourfold is a relatively new recommenda-
tion. Nevertheless, physicians are not sufficiently
confident to use this approach, in part because increas-
ing the dose of antihistamines improves the control of
pruritus significantly but does not reduce the number of
wheals [42]. Moreover, the weaknesses of clinical studies
and their significant heterogeneity limits the consistency
of findings to support this approach [42]. The fear of
possible side effects using higher doses of second-
generation H1 antihistamines is another important fac-
tor among physicians [42].
The prevalence of combined use of first- and second-
generation H1 antihistamines, or the use of a first-
generation H1 antihistamine alone, were relatively low
for our patients (10.7, and 2.7%, respectively). In
Ecuador, some physicians (particularly pediatricians)
commonly use first-generation H1 antihistamines to
treat chronic urticaria [7]. Also, some practice guidelines
continue to recommend them [6]. Ferrer and colleagues
noted that hydroxyzine was the second most frequently
prescribed drug, with no difference in the prevalence of
prescribing between dermatologists and allergists [43]. A
possible explanation could be that first-generation H1
antihistamines cost less than second-generation H1
antihistamines in Ecuador.
Chronic inducible urticaria appears to be more resist-
ant to standard doses of antihistamines compared with
chronic spontaneous urticaria, thus necessitating higher
doses to achieve symptom control [44]. In our patients,
antihistamines alone achieved control of the symptoms
of chronic inducible urticaria whereas, for chronic spon-
taneous urticaria, a combination of different medications
was needed. Unfortunately, we cannot draw any conclu-
sions from this observation.
During the last 14 years, 273 patients have been diag-
nosed with chronic urticaria at our center. No significant
changes in the etiology of urticaria have been found.
Even though urticarial vasculitis is not a type of urti-
caria, it was identified as the principal differential diag-
nosis in our cross sectional study.
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Our has study has some limitations. First, we didn’t as-
sess severity of the disease using the Urticaria Activity
Score (UAS) before and after treatment. By the time
these patients were diagnosed and treated, an official
Spanish version of UAS wasn’t available. Instead, we
used a Visual Analog Scale (VAS) to assess the pruritus
and wheals severity. Second, for clinical entities such as
food and drug associated urticaria, we performed the
diagnosis mostly through anamnesis. A careful clinical
history is recommended for both etiologies, but it relies
on the patient’s awareness and memory, which is a major
downside of major concern for drug associated urticaria.
For food allergy, we complemented diagnosis with spe-
cific IgE. Even though oral food challenge (OFC) is the
gold standard for food allergy diagnosis, we didn’t per-
form such test. For drug associated urticaria, we inter-
preted symptoms resolution after offending drug
removal as a confirmatory finding for diagnosis, though,
more objective tests such as Prick test or in vitro testing
could have been helpful. Third, we didn’t provide any
data concerning follow up, severity, response or quality
of life. This study focusses mainly on the distribution of
urticaria etiology and first therapeutic regimen
prescribed.
Conclusions
Chronic spontaneous urticaria is one of the most preva-
lent subtypes of chronic urticaria. Non-sedating antihis-
tamines in licensed doses are the drug of choice.
Nevertheless, a considerable proportion of patients re-
quire the addition of another type of medication.
There is a need to elucidate the other factors that con-
tribute to the development of chronic urticaria and the
the optimal management of this disease. Furthermore,
we believe that urticarial vasculitis must be excluded as
a differential diagnosis of any subtype of chronic
urticaria.
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